Literature DB >> 35588334

Macrophages evoke autophagy of hepatic stellate cells to promote liver fibrosis in NAFLD mice via the PGE2/EP4 pathway.

Ying Cao1, Weili Mai1,2, Rui Li3,4,5, Shuwei Deng3,4,5, Lan Li3,4,5, Yanxi Zhou3,4,5, Qiushi Qin4,6, Yue Zhang3,4,5, Xingang Zhou7, Ming Han3,4,5, Pu Liang3,4,5, Yonghong Yan3,4,5, Yu Hao3,4,5, Wen Xie8, Jie Yan9, Liuluan Zhu10,11,12.   

Abstract

The pathogenesis of liver fibrosis in nonalcoholic fatty liver disease (NAFLD) remains unclear and the effective treatments have not been explored yet. The activation of hepatic stellate cells (HSCs) is considered as the most critical factor in the progression of liver fibrosis and cirrhosis. Autophagy has recently been identified as a new mechanism to regulate HSC activation. Here, we found that liver macrophages were polarized toward type 2 (M2) during the progression of nonalcoholic steatohepatitis (NASH) and liver fibrosis in both patients and NAFLD mice. Using the methionine-choline-deficient (MCD) diet NAFLD murine model and the in vitro cell culture system, we identified that the M2 macrophages promoted HSC autophagy by secreting prostaglandin E2 (PGE2) and binding its receptor EP4 on the surface of HSCs, which consequently enhanced HSC activation, extracellular matrix deposition, and liver fibrosis. Mechanistically, PGE2/EP4 signals enhanced HSC autophagy through the Erk pathway. A specific PGE2/EP4 antagonist E7046 significantly inhibited M2 macrophage-mediated HSC autophagy and improved liver fibrosis and histopathology in NAFLD mice. Our study provides novel mechanistic insights into the regulation of HSC activation and liver fibrosis. Our findings suggest that the PGE2/EP4 pathway is a promising therapeutic target to prevent NASH progression into cirrhosis.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Autophagy; E7046; Erk1/2; Macrophage polarization; Type 2 macrophage

Mesh:

Substances:

Year:  2022        PMID: 35588334     DOI: 10.1007/s00018-022-04319-w

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  56 in total

Review 1.  Fibrosis--a common pathway to organ injury and failure.

Authors:  Don C Rockey; P Darwin Bell; Joseph A Hill
Journal:  N Engl J Med       Date:  2015-03-19       Impact factor: 91.245

Review 2.  MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.

Authors:  Mohammed Eslam; Arun J Sanyal; Jacob George
Journal:  Gastroenterology       Date:  2020-02-08       Impact factor: 22.682

3.  Inhibiting Interleukin 11 Signaling Reduces Hepatocyte Death and Liver Fibrosis, Inflammation, and Steatosis in Mouse Models of Nonalcoholic Steatohepatitis.

Authors:  Anissa A Widjaja; Brijesh K Singh; Eleonora Adami; Sivakumar Viswanathan; Jinrui Dong; Giuseppe A D'Agostino; Benjamin Ng; Wei Wen Lim; Jessie Tan; Bhairav S Paleja; Madhulika Tripathi; Sze Yun Lim; Shamini Guna Shekeran; Sonia P Chothani; Anne Rabes; Martina Sombetzki; Eveline Bruinstroop; Lio Pei Min; Rohit A Sinha; Salvatore Albani; Paul M Yen; Sebastian Schafer; Stuart A Cook
Journal:  Gastroenterology       Date:  2019-05-09       Impact factor: 22.682

4.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.

Authors:  C A Matteoni; Z M Younossi; T Gramlich; N Boparai; Y C Liu; A J McCullough
Journal:  Gastroenterology       Date:  1999-06       Impact factor: 22.682

5.  Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice.

Authors:  Jean-Philippe Pradere; Johannes Kluwe; Samuele De Minicis; Jing-Jing Jiao; Geum-Youn Gwak; Dianne H Dapito; Myoung-Kuk Jang; Nina D Guenther; Ingmar Mederacke; Richard Friedman; Ana-Cristina Dragomir; Costica Aloman; Robert F Schwabe
Journal:  Hepatology       Date:  2013-08-09       Impact factor: 17.425

Review 6.  Nonalcoholic Steatohepatitis: A Review.

Authors:  Adam C Sheka; Oyedele Adeyi; Julie Thompson; Bilal Hameed; Peter A Crawford; Sayeed Ikramuddin
Journal:  JAMA       Date:  2020-03-24       Impact factor: 56.272

Review 7.  Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease.

Authors:  Juan Pablo Arab; Marco Arrese; Michael Trauner
Journal:  Annu Rev Pathol       Date:  2018-01-24       Impact factor: 23.472

Review 8.  Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.

Authors:  Daniel Q Huang; Hashem B El-Serag; Rohit Loomba
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-12-21       Impact factor: 46.802

Review 9.  Hepatic stellate cells as key target in liver fibrosis.

Authors:  Takaaki Higashi; Scott L Friedman; Yujin Hoshida
Journal:  Adv Drug Deliv Rev       Date:  2017-05-12       Impact factor: 17.873

10.  CXCL6-EGFR-induced Kupffer cells secrete TGF-β1 promoting hepatic stellate cell activation via the SMAD2/BRD4/C-MYC/EZH2 pathway in liver fibrosis.

Authors:  Xiaobo Cai; Zhenghong Li; Qidi Zhang; Yin Qu; Mingyi Xu; Xinjian Wan; Lungen Lu
Journal:  J Cell Mol Med       Date:  2018-08-14       Impact factor: 5.310

View more
  2 in total

1.  Glycyrrhetinic acid regulates impaired macrophage autophagic flux in the treatment of non-alcoholic fatty liver disease.

Authors:  Yadong Fan; Wenjin Dong; Ying Wang; Shan Zhu; Rundong Chai; Zhe Xu; Xiaoyu Zhang; Yiqi Yan; Long Yang; Yuhong Bian
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

Review 2.  Hepatocellular Carcinoma Intrinsic Cell Death Regulates Immune Response and Prognosis.

Authors:  Valli De Re; Anna Rossetto; Alessandro Rosignoli; Elena Muraro; Vito Racanelli; Maria Lina Tornesello; Aron Zompicchiatti; Alessandro Uzzau
Journal:  Front Oncol       Date:  2022-07-07       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.